Roche’s acquisition of Denmark’s venture capital-backed Roche Innovation Center Copenhagen AS suggests rehabilitation of RNA-targeting technology in the biotech community is a fact. The transaction also may help European venture capitalists (VCs) attract extra funds to invest in biotech.
Roche announced it was buying Santaris for an upfront of $250 million and $200 million in contingent payments on Aug